Inhibrx Biosciences (INBX) Cash from Operations (2023 - 2025)
Inhibrx Biosciences (INBX) reported Cash from Operations of 30122000.0 for Q4 2025, up 31.1% year-over-year from 22975921.0 in Q4 2024, and up 10.94% quarter-over-quarter from 33824000.0 in Q3 2025.
Inhibrx Biosciences (INBX) Cash from Operations (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Cash from Operations data on file, last reported at 30122000.0 in Q4 2025.
- Cash from Operations for Q4 2025 came in at 30122000.0, up 31.1% year-over-year; the trailing twelve-month figure through Dec 2025 was 129794000.0 (up 33.24% YoY), and the FY2025 annual result was 129794000.0, up 33.24% from the prior year.
- Cash from Operations advanced to 30122000.0 in Q4 2025 per INBX's latest filing, from 33824000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 29953000.0 in Q2 2025 and troughed at 63050000.0 in Q1 2024.
- A 3-year average of 43526900.0 and a median of 39807500.0 in 2024 frame the typical range for Cash from Operations.
- On a YoY basis, Cash from Operations climbed as much as 47.78% in 2025 and fell as far as 11.7% in 2025.
- A 3-year view of Cash from Operations shows it stood at 56821000.0 in 2023, then increased by 23.06% to 43720000.0 in 2024, then surged by 31.1% to 30122000.0 in 2025.
- Business Quant data shows INBX's Cash from Operations at 30122000.0 in Q4 2025, 33824000.0 in Q3 2025, and 29953000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Inhibrx Biosciences | 186.16 Mn | 186.16 Mn | - | -30.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -30.12 Mn |
| Dec 31, 2025 | -30.12 Mn |
| Sep 30, 2025 | -33.82 Mn |
| Sep 30, 2025 | -33.82 Mn |
| Jun 30, 2025 | -29.95 Mn |
| Jun 30, 2025 | -29.95 Mn |
| Mar 31, 2025 | -35.90 Mn |
| Mar 31, 2025 | -35.90 Mn |
| Dec 31, 2024 | -43.72 Mn |
| Dec 31, 2024 | -43.72 Mn |
| Sep 30, 2024 | -30.28 Mn |
| Sep 30, 2024 | -30.28 Mn |
| Jun 30, 2024 | -57.36 Mn |
| Jun 30, 2024 | -57.36 Mn |
| Mar 31, 2024 | -63.05 Mn |
| Mar 31, 2024 | -63.05 Mn |
| Dec 31, 2023 | -56.82 Mn |
| Dec 31, 2023 | -56.82 Mn |
| Sep 30, 2023 | -54.25 Mn |
| Sep 30, 2023 | -54.25 Mn |